STD Testing Devices Market accounted for USD 70.29 Billion in 2018 and is expected to register a CAGR of 9.3% during the forecast period.
Sexually transmitted disease (STDs) is an infection caused due to some organisms. STDs can be transmitted from one person to another through sexual activity and intimate contact. The cases of sexually transmitted diseases keep climbing among 45 and older Americans. 82,938 cases of gonorrhea, syphilis, and chlamydia were reported among 45 and older Americans in the year 2016.
The increasing prevalence of lifestyle diseases, rising geriatric population along with increasing awareness about sex-related diseases is influencing the market growth positively. The increasing number of product launches by key players in the market are likely to act as a promising factor for the increase in the near future. For Instance, Quest Diagnostics launched three new sexually transmitted disease (STD) laboratory test packages that individuals can purchase online for some of the most prevalent STDs in the United States.
|Market Size||70.29 Billion|
|Forecast Units||Value (USD Billion)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, End User and Region|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Abbott (US), MedMira Inc. (Canada), Qaigen Inc. (US), Thermo Fisher Scientific (US), Cepheid (Danaher Corporation) (US), Hoffmann-La Roche AG (Switzerland), Diasorin S.p.A (Italy), Bio-Rad Laboratories, bioMeriuex (France), Becton Dickinson and Company (US), Hologic, Inc. (US), GenePOC Inc. (Canada), Meridian Bioscience (US), OraSure Technologies (US)|
|Key Market Opportunities||
|Key Market Drivers||
The valuation of the global STD testing devices market had reached USD 70.29 BN in 2018.
The global STD testing devices market is projected to grow at approximately 9.3% CAGR during the forecast period (2019-2025).
Increasing awareness about intercourse-related diseases.
North America holds the largest share in the global STD testing devices market, followed by Europe and the Asia Pacific, respectively.
MedMira Inc. (Canada), Abbott (US), Qaigen Inc. (US), Cepheid (Danaher Corporation) (US), Thermo Fisher Scientific (US), Hoffmann-La Roche AG (Switzerland), Bio-Rad Laboratories, Inc. (US), Diasorin S.p.A (Italy), bioMeriuex (France), Hologic, Inc. (US), Becton Dickinson and Company (US), GenePOC Inc. (Canada), OraSure Technologies (US), and Meridian Bioscience (US), are some of the major players operating in the STD testing devices market.